The company's principal activities are to develop, market and sell innovative products to guide and improve the treatment of viral diseases. The company develops a way of directly measuring the impact of genetic mutations on drug resistance and using this information to guide therapy. The company has a proprietary technology called phenosense, for testing drug resistance in viruses that cause serious diseases such as aids, hepatitis b and hepatitis c. It collects phenosense test results and related clinical data in an interactive database that can be made available to physicians for use in therapy guidance.
